PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.00 - 0.01
0.00 - 0.02
1.30M / 496.9K (Avg.)
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-4.76%
Negative revenue growth while XRF.AX stands at 24.57%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
1.59%
Gross profit growth under 50% of XRF.AX's 13.07%. Michael Burry would be concerned about a severe competitive disadvantage.
59.24%
EBIT growth above 1.5x XRF.AX's 12.93%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
59.24%
Operating income growth above 1.5x XRF.AX's 12.93%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
-96.52%
Negative net income growth while XRF.AX stands at 35.84%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.93%
Share reduction more than 1.5x XRF.AX's 22.68%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
1.93%
Diluted share reduction more than 1.5x XRF.AX's 22.68%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
97.84%
OCF growth above 1.5x XRF.AX's 41.17%. David Dodd would confirm a clear edge in underlying cash generation.
69.41%
FCF growth 1.25-1.5x XRF.AX's 56.25%. Bruce Berkowitz would see if capex decisions or cost controls create a cash flow advantage.
-90.53%
Negative 10Y revenue/share CAGR while XRF.AX stands at 30.52%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-56.69%
Negative 5Y CAGR while XRF.AX stands at 30.52%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-57.18%
Negative 3Y CAGR while XRF.AX stands at 8.66%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
-100.04%
Negative 10Y OCF/share CAGR while XRF.AX stands at 4540.47%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
99.83%
Below 50% of XRF.AX's 4540.47%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
-100.40%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-99.95%
Negative 10Y net income/share CAGR while XRF.AX is at 875.24%. Joel Greenblatt sees a major red flag in long-term profit erosion.
100.07%
Below 50% of XRF.AX's 875.24%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
100.31%
3Y net income/share CAGR above 1.5x XRF.AX's 32.24%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
6.30%
R&D growth of 6.30% while XRF.AX is zero. Bruce Berkowitz checks if the moderate investment leads to meaningful product differentiation.
-15.35%
We cut SG&A while XRF.AX invests at 10.93%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.